Clinical trial Recruiting at 1 site Interventional Ages 20 to 80

Wearable, voice-guided BBTi for COMISA (insomnia + sleep apnea)

Official title: Wearable Voice-Guided Brief Behavioral Therapy for Insomnia (BBTi) for Comorbid Insomnia and Sleep Apnea (COMISA): Effects on Insomnia Severity and CPAP Adherence From Mechanism Evaluation and Device Development to a Multicenter Randomized Controlled Trial

Run by National Sun Yat-sen University · NCT07521319 · Data updated 2026-11-12

A wearable, voice-guided Brief Behavioral Therapy for Insomnia (BBTi) combined with a smart eye-mask is being tested to see if it helps adults with COMISA improve sleep and CPAP adherence.

Quick facts

Study typeInterventional
Ages20 Years to 80 Years
SexAll
Enrollment361 (estimated)
SponsorNational Sun Yat-sen University
Academic / other
Locations1 site (Tainan, Taiwan)
StatusRecruiting
StartedAugust 1, 2026
Main results expectedJuly 31, 2030
Study endsDecember 31, 2030
Registry record updatedOctober 15, 2026
Trial IDNCT07521319 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 20 years and older with comorbid insomnia and obstructive sleep apnea who meet DSM-5 insomnia criteria and have ISI ≥15.

Probably not a fit

Individuals without COMISA, those with contraindications to BBTi or the eye-mask device, or those not meeting eligibility may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project tests a wearable, home-based approach that blends BBTi with a smart eye-mask that provides voice-guided sessions and relaxation features. The study has three phases: understanding why COMISA patients struggle with sleep, developing and testing the integrated eye-mask with BBTi content, and a multi-center randomized trial comparing the combined intervention to BBTi alone, eye-mask alone, or standard sleep hygiene. Primary outcomes include insomnia severity, daytime sleepiness, and CPAP adherence. The trial aims to establish an evidence-based digital intervention to improve sleep health in COMISA patients.

Why it matters

Potential benefit: If successful, participants may sleep better, feel more rested, and use CPAP more consistently.

How similar studies have gone: Prior studies suggest behavioral sleep interventions can improve insomnia symptoms, but combining BBTi with a wearable, voice-guided system for COMISA is a novel approach with limited prior data.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age ≥20 years.
* Obstructive sleep apnea (OSA) diagnosed by clinical polysomnography (PSG), defined as apnea-hypopnea index (AHI) ≥5 events/hour.
* Insomnia disorder diagnosed by a physician according to DSM-5 criteria, with Insomnia Severity Index (ISI) score ≥15.
* Able to understand study procedures and provide written informed consent.

Exclusion Criteria:

* Severe cognitive impairment,
* Major psychiatric disorder,
* Severe chronic illness (e.g., severe heart failure or receiving hemodialysis).
* Other sleep disorders (e.g., restless legs syndrome, narcolepsy, circadian rhythm sleep-wake disorders).
* Receipt of CBT-I, BBTi, or other behavioral sleep interventions within the past 3 months.
* Pregnant or breastfeeding.

Where it's running

  • National Cheng Kung University Hospital
    Tainan, Taiwan, Taiwan
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.